A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Sponsor: MacroGenics
Listed as NCT05293496, this PHASE1 trial focuses on Advanced Solid Tumor and Castration-Resistant Prostatic Cancer and remains completed. Sponsored by MacroGenics, it has been updated 16 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
16 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Aug 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
-
Jun 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
-
Dec 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1
▶ Show 11 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Aug 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Jun 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Apr 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Feb 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — Jun 2022 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- MacroGenics
For direct contact, visit the study record on ClinicalTrials.gov .